Through years of private equity fund raises and partnerships, Lyndra Therapeutics has been building up its strategy to bring once-weekly or monthly oral medications to the health care system. With a $101m series E fundraising and a related commercial rights alliance with Sun Pharmaceutical Industries Ltd. unveiled on 21 December, the Watertown, MA-based company appears to be getting closer to that goal.
Key Takeaways
-
Drug delivery specialist Lyndra raises $101m in series E cash, with some of the money coming from Sun Pharma in exchange for commercial rights to its lead product candidate.
In January, Lyndra plans to release data from a Phase III pharmacokinetic study of LYN-005, its weekly, oral formulation of...